Linc00963: A novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence

Wang,Lijuan; Han,Suxia; Jin,Guihua; Zhou,Xia; Li,Meng; Ying,Xia; Wang,Le; Wu,Huili; Zhu,Qing

doi:10.3892/ijo.2014.2363

Linc00963: A novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence

Authors:
- Lijuan Wang
- Suxia Han
- Guihua Jin
- Xia Zhou
- Meng Li
- Xia Ying
- Le Wang
- Huili Wu
- Qing Zhu
View Affiliations

Affiliations: Department of Oncology, the First Affiliated Hospital, Xi'an Jiaotong University of Medical College, Xi'an 710061, P.R. China
Published online on: April 2, 2014 https://doi.org/10.3892/ijo.2014.2363
Pages: 2041-2049

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Whole genome transcriptomic analyses have identified a large number of long non-coding RNAs (lncRNAs), many of which are involved in a variety of biological functions. However, their functions and molecular mechanisms associated with prostate cancer (PCa) progression to a virulent and androgen-independent (AI) form remain elusive. Herein, we investigated the lncRNA expression profiles of the indolent, androgen-dependent (AD) LNCaP cell line to the aggressive metastatic, AI C4-2 cell line using microarray technology. The differentially expressed lncRNAs and genes were identified by microarray technology and the association in cis or in trans was analyzed to find potential lncRNA target genes. Expression of candidate lncRNAs and putative targets was evaluated by real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The functions of linc00963 on cell proliferation, apoptosis, migration and invasion were evaluated by a knockdown strategy in vitro using MTT, flow cytometric analysis and transwell chamber assays. lncRNAs (n=134) were differentially expressed (FDR <0.001 and fold change ≥2) between the LNCaP and C4-2 cell lines. Linc00963 was upregulated most obviously evaluated by qRT-PCR. Knockdown of linc00963 attenuated C4-2 cell proliferation, motility, invasion ability, the expression of EGFR and phosphorylation levels of AKT, and promoted cell apoptosis. Linc00963 was involved in the prostate cancer transition from androgen-dependent to androgen-independent and metastasis via the EGFR signaling pathway.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2.	Lee AK: Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol. 16:20–28. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Molina A and Belldegrun A: Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol. 185:787–794. 2011. View Article : Google Scholar
4.	Mlcochova J, Faltejskova P, Nemecek R, Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol. 139:1615–1624. 2013. View Article : Google Scholar : PubMed/NCBI
5.	Shuch B, Mikhail M, Satagopan J, et al: Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 22:4725–4729. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Syed S: Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls. Cancer. 98:2088–2090. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Traish AM and Morgentaler A: Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 101:1949–1956. 2009. View Article : Google Scholar
8.	Antonarakis ES, Carducci MA and Eisenberger MA: Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 291:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Guttman M, Amit I, Garber M, et al: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Gupta RA, Shah N, Wang KC, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Reis EM, Nakaya HI, Louro R, et al: Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene. 23:6684–6692. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Prensner JR, Iyer MK, Balbin OA, et al: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 29:742–749. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Ji P, Diederichs S, Wang W, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Petrovics G, Zhang W, Makarem M, et al: Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 23:605–611. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Srikantan V, Zou Z, Petrovics G, et al: PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA. 97:12216–12221. 2000. View Article : Google Scholar : PubMed/NCBI
17.	Chung S, Nakagawa H, Uemura M, et al: Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 102:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Cui Z, Ren S, Lu J, et al: The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol. 31:1117–1123. 2013. View Article : Google Scholar : PubMed/NCBI
19.	Lin R, Maeda S, Liu C, Karin M and Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 26:851–858. 2007. View Article : Google Scholar : PubMed/NCBI
20.	de Kok JB, Verhaegh GW, Roelofs RW, et al: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62:2695–2698. 2002.
21.	Hessels D, Klein Gunnewiek JM, van Oort I, et al: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 44:8–16. 2003. View Article : Google Scholar
22.	Xie BX, Zhang H, Yu L, et al: The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl. 12:405–414. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Horoszewicz JS, Leong SS, Kawinski E, et al: LNCaP model of human prostatic carcinoma. Cancer Res. 43:1809–1818. 1983.
24.	Thalmann GN, Anezinis PE, Chang SM, et al: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581. 1994.PubMed/NCBI
25.	Chen L, Mooso BA, Jathal MK, et al: Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 17:6218–6228. 2011. View Article : Google Scholar
26.	Gutschner T and Diederichs S: The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar
28.	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW and Griffin JL: The contrasting roles of PPARdelta and PPARgamma in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol. 12:R752011. View Article : Google Scholar : PubMed/NCBI
30.	Cheng W, Zhang Z and Wang J: Long noncoding RNAs: New players in prostate cancer. Cancer Lett. 339:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
31.	Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59:5975–5979. 1999.PubMed/NCBI
32.	Bu D, Yu K, Sun S, et al: NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res. 40:D210–D215. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Takayama K, Horie-Inoue K, Katayama S, et al: Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 32:1665–1680. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Mimeault M and Batra SK: Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 27:1–22. 2006. View Article : Google Scholar : PubMed/NCBI
35.	Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61:6276–6280. 2001.PubMed/NCBI
36.	Xie BX, Zhang H, Wang J, et al: Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl. 32:170–182. 2011. View Article : Google Scholar : PubMed/NCBI